Refined And Quantified Dry Extract Of Ginkgo Biloba Leaves (35-67:1) Quantified To 22.0 To 27.0 % Of Flavonoids Expressed As Flavone Glycosides, 2.8 To 3.4 % Of Ginkgolides A, B And C, And 2.6 To 3.2 % Of Bilobalide. Extraction Solvent: Acetone 60% (M/M)

1 trials NNeurology/Psychiatry

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

1 Sponsors

3 Countries

Phase II

Phase II: 1

Indications tested

Cognitive disorder 1 Post-acute COVID-19 syndrome 1

Sponsors using this IMP

Dr. Willmar Schwabe GmbH & Co. KG 1

All trials

1 total

A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po… Ended

2024-517199-39-00 Phase II 3 countries Dr. Willmar Schwabe GmbH & Co. KG

Showing 1–1 of 1 trials

← All drugs A–Z